European Society of Cutaneous Lupus Erythematosus (EUSCLE)

Status Enrolling by invitation

Clinical Trial Summary

Cutaneous lupus erythematosus (CLE) is a disease with a wide spectrum of clinical manifestations and a variable prognosis. The aim of the study is to create a standardized evaluation of the different subtypes of this disease in order to receive an overview of the spectrum of clinical and laboratory features as well as the therapeutic strategies for patients with CLE.

Clinical Trial Description

Methods: A core set questionnaire has been developed in the course of the "European Society of Cutaneous Lupus Erythematosus (EUSCLE)", and a total of 40 patients (32 females, 8 males) in two centres, Germany and Sweden, were included in this study. Results: CLE was diagnosed in 39 individuals (5 with acute CLE, 10 with subacute CLE, 13 with chronic CLE, and 18 with intermittent CLE) and one individual presented with a systemic manifestation of the disease. Furthermore, disease onset and duration as well as activity and damage of skin lesions using a modified CLASI were examined. Interestingly, 75% of the patients with CLE showed a positive history of photosensitivity, but only 62.5% exhibited characteristic lesions after standardized phototesting. Laboratory analysis revealed positive antinuclear antibodies in 50% of the patients, positive anti-Ro/SSA in 12 and positive anti-La/SSB antibodies in 8 cases. The predominantly used treatments included sunscreens (38 patients), topical steroids (31 patients), topical calcineurin inhibitors (12 patients), chloroquine (19 patients), hydroxychloroquine (11 patients), and systemic steroids (12 patients). Conclusions: The new core set questionnaire enables the clinician to characterize the different skin manifestations involved in CLE and to evaluate disease activity and reasonable treatment modalities. Furthermore, epidemiological data and laboratory features can be assessed for the various subtypes. In the future, this standardized evaluation might lead to the development of diagnostic guidelines and evidence based therapeutic strategies thus improving quality of care for patients with CLE. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00420121
Study type	Observational
Source	European Society of Cutaneous Lupus Erythematosus e.V.
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	January 2007
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Recruiting	`NCT05967520` - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus	Phase 2
Completed	`NCT02875691` - Effect of Green Tea on Treatment of Lupus	Phase 2
Completed	`NCT02922114` - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients	N/A
Withdrawn	`NCT01702038` - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE	Phase 2
Terminated	`NCT00368264` - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )	Phase 2/Phase 3
Completed	`NCT00094380` - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)	Phase 1/Phase 2
Completed	`NCT00065806` - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A
Recruiting	`NCT03543839` - Trial of Belimumab in Early Lupus	Phase 4
Completed	`NCT03098823` - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE	Phase 4
Recruiting	`NCT05899907` - Efficacy and Safety of Telitacicept in Early SLE	Phase 4
Completed	`NCT04956484` - Belimumab In Early Systemic Lupus Erythematosus	Phase 4
Completed	`NCT05326841` - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .	Phase 3
Completed	`NCT02655640` - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis	N/A
Completed	`NCT02034344` - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers	Phase 0
Terminated	`NCT00089804` - Study of LJP 394 in Lupus Patients With History of Renal Disease	Phase 3
Completed	`NCT00071487` - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)	Phase 2
Completed	`NCT02349061` - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus	Phase 2
Recruiting	`NCT05636670` - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.